Whalen Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Whalen Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$199K	Buy	+48,282	New	+$164K	0.09%	199

Other funds holding RXRX

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return

Whalen Wealth Management's RXRX Position: Q3 2026 in Review

Whalen Wealth Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2026: 48,282 shares worth $199K. The stake represents 0.09% of the portfolio and ranks #199 among its holdings.

20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Whalen Wealth Management held 48,282 shares of Recursion Pharmaceuticals worth $199K as of Q3 2026.
Recursion Pharmaceuticals was a new Whalen Wealth Management position in Q3 2026.
Recursion Pharmaceuticals made up 0.09% of Whalen Wealth Management's portfolio in Q3 2026, its #199 holding.
20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Whalen Wealth Management's 13F filing for Q3 2026, filed 8 Oct 2026.